Clinical trials: Mucormycosis
Maxillofacial Trauma, Face Cancer
Evaluation of Using 3D Printed PEEK Facial Implants in Repairing Maxillofacial Deformities
Objective: Evaluation of using 3D printed polyether ether ketone facial implants in repairing maxillofacial deformities. Research materials and methods: The research sample consisted of 10 patients with facial deformities…
- Conditions
- Maxillofacial Trauma, Face Cancer, Mucormycosis
- Trial name
- NCT05348434
- Testing
- 3D printed polyether ether ketone facial implants in repairing maxillofacial deformities
- Where
- Syria
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Latakia University
Mucormycosis; Rhinocerebral (Etiology), COVID-19
World Health Organization (WHO) , COVID19 Case Series of Post Covid 19 Rhino Orbito Cerebral Mucormycosis in Egypt
Objectives: identify and recognize clinical Characteristics, Pathophysiology, and management of a group of patients with rhino Rhino-Orbito-Cerebral Mucormycosis infection associated with Covid 19 viral infection
- Trial name
- NCT06267326
- Testing
- debridment
- Where
- Egypt
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Nasser Institute For Research and Treatment
Aspergillos, Mucormye
Assessment of [18F]-Fluorocellobiose ([18F]FCB) Pharmacokinetics in Healthy Volunteers and Subjects With Invasive Mold Infections
Background: Fungal infections can cause serious disease in the lungs and other parts of the body. About 3.8 million people die with fungal infections each year.
- Conditions
- Aspergillos, Mucormye, Dimorphic, Other Molds
- Trial name
- NCT07704333
- Testing
- [18F]-Fluorocellobiose ([18F]FCB)
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Mucorales Infection, Mucormycosis
Biomarkers for Invasive Mucormycosis
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization.
- Trial name
- BIM (NCT05406037)
- Testing
- Venous sample
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille